Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse

American Journal of Hematology

Volumn 88, Issue 5, 2013, Pages 359-364

  Martínez Laperche, Carolina ^a   Gómez García, Ana M ^a   Lassaletta, Álvaro ^a   Moscardó, Cristina ^b   Vivanco, José L ^c   Molina, Javier ^d   Fuster, José L ^e   Couselo, José M ^f   De Toledo, José Sánchez ^g   Bureo, Encarnación ^h   Madero, Luis ^a   Ramírez, Manuel ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f Instituto de Salud Carlos III   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER DIAGNOSIS; CENTRAL NERVOUS SYSTEM LEUKEMIA; CEREBROSPINAL FLUID; CHILD; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INFANT; KARYOTYPE; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; T CELL LEUKEMIA;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INJECTIONS, SPINAL; MAINTENANCE CHEMOTHERAPY; MALE; MENINGEAL NEOPLASMS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SPAIN; SURVIVAL ANALYSIS;

EID: 84876724554     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23407     Document Type: Article

References (32)

1. Aur RJ, Simone J, Hustu HO, et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 1971;37:272-281.
2. Simone JV. History of the treatment of childhood ALL: A paradigm for cancer cure. Best Pract Res Clin Haematol 2006;19: 353-359; review.
3. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178; review.
4. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008;9:257-268; review.
5. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000;14:2247-2256.
6. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000;14:2286-2294.
7. Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 1993;329:314-319.
8. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
9. Bürger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003;21:184-188.
10. de Haas V, Vet RJ, Verhagen OJ, et al. Early detection of central nervous system relapse by polymerase chain reaction in children with B-precursor acute lymphoblastic leukemia. Ann Hematol 2002;81:59-61.
11. Schroers R, Baraniskin A, Heute C, et al. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol 2010;85:520-528.
12. Quijano S, López A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: Improved sensitivity of flow cytometry. J Clin Oncol 2009;27:1462-1469.
13. Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007;68:1674-1679.
14. Subirá D, Castañón S, Román A, et al. Flow cytometry and the study of central nervous disease in patients with acute leukaemia. Br J Haematol 2001;112:381-384.
15. Brem SS, Bierman PJ, Black P, et al. Central nervous system cancers. J Natl Compr Canc Netw 2008;6:456-504.
16. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology. Blood 2005;105:496-502.
17. Dworzak MN, Fröschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99:1952-1958.
18. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96 :2691-2696.
19. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 1995;85:1416-1434.
20. Biojone E, Queiróz RD, Valera ET, et al. Minimal residual disease in cerebrospinal fluid at diagnosis: A more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia. Leuk Lymphoma 2012;53:89-95.
21. Scrideli CA, Queiroz RP, Takayanagui OM, et al. Polymerase chain reaction on cerebrospinal fluid cells in suspected leptomeningeal involvement in childhood acute lymphoblastic leukemia: Comparison to cytomorphological analysis. Diagn Mol Pathol 2003;12:124-127.
22. Pine SR, Yin C, Matloub YH, et al. Detection of central nervous system leukemia in children with acute lymphoblastic leukemia by real-time polymerase chain reaction. J Mol Diagn 2005;7:127-132.
23. Gururangan S, Sposto R, Cairo MS, et al. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: A Children's Cancer Group study. J Clin Oncol 2000;18:2017-2025.
24. Akers SM, Rellick SL, Fortney JE, et al. Cellular elements of the subarachnoid space promote ALL survival during chemotherapy Leuk Res 2011;35:705-711.
25. Jahnukainen K, Saari T, Salmi TT, et al. Reactions of Leydig cells and blood vessels to lymphoblastic leukemia in the rat testis. Leukemia 1995;9:908-914.
26. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
27. Neale GA, Pui CH, Mahmoud HH, et al. Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia. Leukemia 1994;8:768-775.
28. Lal A, Kwan E, al Mahr M, et al. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse. Mol Pathol 1998;51:277-281.
29. Uckun FM, Gaynon PS, Stram DO, et al. Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineageacute lymphoblastic leukemia patients with an isolated extramedullary first relapse. Clin Cancer Res 1999;5:2415-2420.
30. Hagedorn N, Acquaviva C, Fronkova E, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: A more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood 2007;110:4022-4029.
31. Badell I, Muñoz A, Estella J, et al. Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP)from 1989 to 1998. Clin Transl Oncol 2008;10:117-124.
32. Ortega JJ, Ribera JM, Oriol A, et al. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Haematologica 2001;86:586-595.